公开(公告)号：US20240336901A1

公开(公告)日：2024-10-10

申请号：US18654176

申请日：2024-05-03

Applicant: Temple University-Of The Commonwealth System of Higher Education

Inventor： Richard T. Pomerantz ,  Tatiana Kent

IPC: C12N9/12 ,  C07H21/04 ,  C12P19/34 ,  C12Q1/68 ,  C12Q1/6806 ,  C12Q1/6827 ,  C12Q1/6844 ,  C12Q1/6853

CPC classification number: C12N9/1252 ,  C12P19/34 ,  C12Q1/68 ,  C12Q1/6806 ,  C12Q1/6827 ,  C12Q1/6844 ,  C12Q1/6853 ,  C07H21/04 ,  C12N2310/344 ,  C12Q2521/101 ,  C12Q2525/101 ,  C12Q2563/137 ,  C12Y207/07007

Abstract: The invention provides compositions and methods for modifying the 3′-terminal ends of nucleic acids using DNA polymerase θ terminal transferase activity.

公开(公告)号：US20240329033A1

公开(公告)日：2024-10-03

申请号：US18515636

申请日：2023-11-21

Applicant: Temple University-Of The Commonwealth System of Higher Education

Inventor： Jay Rappaport ,  Sarah Vakili

IPC: G01N33/50 ,  C07K14/705 ,  C07K14/73 ,  C07K14/735 ,  C12N5/0786

CPC classification number: G01N33/5047 ,  C07K14/70514 ,  C07K14/70535 ,  C07K14/70596 ,  C12N5/0645 ,  C12N2501/052 ,  C12N2501/22 ,  C12N2501/24 ,  C12N2501/25 ,  C12N2501/30 ,  C12N2501/39 ,  C12N2501/999

Abstract: The invention provides monocytes expressing CD16 and CD163 and experimental system for drug screening or evaluating drug candidates where the modulation of CD16 and CD163 is desired.

公开(公告)号：US20240261436A1

公开(公告)日：2024-08-08

申请号：US18566468

申请日：2022-06-02

Applicant: TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION

Inventor： Kamel KHALILI ,  Rafal KAMINSKI

IPC: A61K48/00 ,  A61K31/4985 ,  A61K31/505 ,  A61K31/52 ,  A61K31/7068 ,  A61P31/18 ,  C12N9/22 ,  C12N15/113

CPC classification number: A61K48/005 ,  A61K31/4985 ,  A61K31/505 ,  A61K31/52 ,  A61K31/7068 ,  A61P31/18 ,  C12N9/22 ,  C12N15/1132 ,  C12N15/1138 ,  C12N2310/20

Abstract: Compositions for specifically cleaving target sequences in retroviruses include nucleic acids encoding a Clustered Regularly Interspace Short Palindromic Repeat (CRISPR) associated endonuclease and a guide RNA sequence complementary to a target sequence in a retrovirus and a receptor used by a retrovirus for infecting a cell. The CRISPR construct edits, for example, proviral HIV DNA, thereby eliminating the provirus from an infected cell and simultaneously edits a viral receptor, e.g. CCR5 preventing infection and reinfection of the host.

公开(公告)号：US20240245607A1

公开(公告)日：2024-07-25

申请号：US18426838

申请日：2024-01-30

Applicant: Temple University-Of The Commonwealth System of Higher Education

Inventor： Gregory S. Smutzer ,  Kevin Lee ,  Dhruti Patel

IPC: A61K9/16 ,  A61K9/00 ,  A61K31/01 ,  A61K31/015 ,  A61K31/047 ,  A61K31/12 ,  A61K31/165 ,  A61K31/192 ,  A61K31/353 ,  A61K31/355 ,  A61K31/366 ,  A61K31/704 ,  A61K36/185 ,  A61K47/10 ,  A61K47/22 ,  A61K47/24 ,  A61K47/26 ,  A61K47/36 ,  A61K47/38 ,  A61K47/46

CPC classification number: A61K9/1617 ,  A61K9/0056 ,  A61K9/1623 ,  A61K9/1682 ,  A61K31/01 ,  A61K31/015 ,  A61K31/047 ,  A61K31/12 ,  A61K31/165 ,  A61K31/192 ,  A61K31/353 ,  A61K31/355 ,  A61K31/366 ,  A61K31/704 ,  A61K36/185 ,  A61K47/10 ,  A61K47/22 ,  A61K47/24 ,  A61K47/26 ,  A61K47/36 ,  A61K47/38 ,  A61K47/46

Abstract: The present invention relates to compositions and methods for masking the taste of an agent. In certain aspects, the invention comprises a microsphere and at least one sweetener therein. In another aspect, the invention comprises an edible material comprising at least one microsphere comprising an agent and at least one microsphere comprising a sweetener.

公开(公告)号：US20240238346A1

公开(公告)日：2024-07-18

申请号：US18577300

申请日：2022-07-08

Applicant: Temple University - of the Commonwealth System of Higher Education

Inventor： Sadia MOHSIN ,  Steven HOUSER ,  Hajime KUBO

IPC: A61K35/28 ,  A61K38/17 ,  A61P9/00

CPC classification number: A61K35/28 ,  A61K38/1754 ,  A61K38/1793 ,  A61P9/00

Abstract: Cell therapies and cell secretome compositions are utilized in the methods of treatment of cardiac injury. The compositions mediate myocardial homeostasis and cardiac wound healing process post-MI via the direct modulation of regulatory T cell (Treg) population dynamics and function.

公开(公告)号：US20240139294A1

公开(公告)日：2024-05-02

申请号：US18298913

申请日：2023-04-11

Applicant: Temple University - of the Commonwealth System of Higher Education

Inventor： Kamel KHALILI ,  Wenhui Hu

IPC: A61K38/46 ,  A61K9/00 ,  A61K35/12 ,  A61K45/06 ,  A61K48/00 ,  C12N7/00 ,  C12N9/22 ,  C12N15/11

CPC classification number: A61K38/465 ,  A61K9/0034 ,  A61K35/12 ,  A61K45/06 ,  A61K48/00 ,  A61K48/005 ,  C12N7/00 ,  C12N9/22 ,  C12N15/111 ,  C12N2310/20 ,  C12N2320/30 ,  C12N2740/16063 ,  C12Y301/21

Abstract: A method of preventing transmission of a retrovirus from a mother to her offspring, by administering to the mother a therapeutically effective amount of a composition comprising a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease, and the two or more different multiplex gRNAs, wherein each of the at least two gRNAs is complementary to a different target nucleic acid sequence in a long terminal repeat (LTR) of proviral DNA of the virus that is unique from the genome of the host cell, cleaving a double strand of the proviral DNA at a first target protospacer sequence with the CRISPR-associated endonuclease, cleaving a double strand of the proviral DNA at a second target protospacer sequence with the CRISPR-associated endonuclease, excising an entire HIV-1 proviral genome, eradicating the HIV-1 proviral DNA from the host cell, and preventing transmission of the proviral DNA to the offspring.

公开(公告)号：US11963938B2

公开(公告)日：2024-04-23

申请号：US17379305

申请日：2021-07-19

Applicant: Temple University-Of The Commonwealth System of Higher Education

Inventor： Mark A. Feitelson

IPC: A61K31/19 ,  A61K9/00 ,  A61K35/744 ,  A61K35/747 ,  A61P35/00

CPC classification number: A61K31/19 ,  A61K9/0053 ,  A61K35/744 ,  A61K35/747 ,  A61P35/00

Abstract: The invention relates to compositions for preventing or delaying the onset of hepatocellular cancer. The compositions of the invention may comprise short chain fatty acids. The compositions of the invention may also comprise probiotic bacteria. The compositions of the invention include compositions for preventing or delaying the onset of hepatocellular cancer by treating or preventing liver inflammation, liver disease, and precancerous lesions.

公开(公告)号：US20240058283A1

公开(公告)日：2024-02-22

申请号：US18336712

申请日：2023-06-16

Applicant: West Virginia University Board of Governors on Behalf of West Virginia University ,  Temple University-Of the Commonwealth System of Higher Education ,  University of Pittsburgh-Of the Commonwealth System of Higher Education ,  The United States Government as represented by the Department of Veterans Affairs

Inventor： John B. Barnett ,  Werner Geldenhuys ,  Jonathan Soboloff ,  Harry C. Blair

IPC: A61K31/167

CPC classification number: A61K31/167

Abstract: A method of restoring the balance of osteoclast to osteoblast activity in a patient having rheumatoid arthritis comprising administering to a patient a therapeutically effective amount of the compound N-(3,4-dichlorophenyl)-N-methylpropanamide is provided. A method for treating arthritis-induced bone erosion in a patient comprising administering to a patient a therapeutically effective amount of the compound N-(3,4-dichlorophenyl)-N-methylpropanamide is provided. The compound N-(3,4-dichlorophenyl)-N-methylpropanamide is administered in a pharmaceutically acceptable composition to said patient. A mode of action of N-(3,4-dichlorophenyl)-N-methyl propanamide comprising targeting transient receptor potential channels is provided.

公开(公告)号：US11897870B2

公开(公告)日：2024-02-13

申请号：US16861075

申请日：2020-04-28

Applicant: Temple University Of The Commonwealth System of Higher Education

Inventor： Daniel J. Canney ,  Benjamin E. Blass ,  Rong Gao ,  Magid Abou-Gharbia

IPC: C07D405/12 ,  C07D405/06 ,  C07D307/94 ,  C07D307/33

CPC classification number: C07D405/12 ,  C07D307/33 ,  C07D307/94 ,  C07D405/06

Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.

公开(公告)号：US11846629B2

公开(公告)日：2023-12-19

申请号：US16334808

申请日：2017-09-20

Applicant: Temple University—Of The Commonwealth System of Higher Education

Inventor： Jay Rappaport ,  Sarah Vakili

IPC: C07K14/705 ,  C07K14/73 ,  C07K14/735 ,  C12N5/0786 ,  G01N33/50

CPC classification number: G01N33/5047 ,  C07K14/70514 ,  C07K14/70535 ,  C07K14/70596 ,  C12N5/0645 ,  C12N2501/052 ,  C12N2501/22 ,  C12N2501/24 ,  C12N2501/25 ,  C12N2501/30 ,  C12N2501/39 ,  C12N2501/999

Abstract: The invention provides monocytes expressing CD16 and CD163 and experimental system for drug screening or evaluating drug candidates where the modulation of CD16 and CD163 is desired.